NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Yes, under the right circumstances, stocks can go up significantly on capital raises.

FATE, a crazy innovative immuno-oncology company using highly engineered stem cells to produce NK cells and T-cells, issued 6.2 million shares at $28.31 (the closing price on 6/8). A 7.7% dilution but raised $175.5 million to push forward their burgeoning pipeline in what is one of the most competitive niches is the market. Time to make hay.

It opened the next day at $29.70, hit a high of $35.77 and closed at $32.72, for a 15.6% gain. The open price was essentially the low price since then. It is currently trading at $48.

It is up 240% in the last year, sitting at a $4.2 billion market cap. In terms of trial results, they’ve treated and reported less than a handful of patients in a phase 1 trial but saw some extremely positive responses.